The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
|Articles|June 21, 2023
Mass Spectrometry Imaging: Top 8 benefits in oncology drug discovery and development
Author(s) Pyxant
Mass spectrometry imaging (MSI) is beneficial in early development and murine models across many therapeutic areas. This technique is especially suited for oncology due to the availability of tissue.
Related to this article
USP data show fewer US drug shortages but longer ones, averaging 5+ years. Drug shortages are an incentive problem, not a manufacturing mystery.
Boehringer, AbbVie, ASKA, and Evommune license ADC, IBD, thyroid eye disease, and degrader assets, raising tech transfer demands for manufacturers.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
Vivek Gupta of Duquesne University explains at AAPS PharmSci 360 why device decisions can't wait and why excipient makers must test beyond drug molecules.
Industry subject matter experts spoke about the challenges of turning complex molecules into medicines patients can reliably use.
The pharmaceutical supply chain is a complex system with high stakes. USP provides insights on how it is helping industry navigate global disruptions and procurement issues.
Jaenisch, Muraru, and Pandey discuss how regulators will audit pharma against its own AI policies and ways QA and regulatory teams can build defensible, inspection-ready AI practices.
Trending on Pharmaceutical Technology
1
Improving Oral Peptide Delivery Through Structural Modifications
2
Drapeau’s AI Deep Dive: The Price of Acceptance in Regulated AI
3
AAPS PharmSci 360: How USP Is Tackling the Novel Excipient Roadblock
4
Using OEE Monitoring to Justify Expenditure on Aging Production Lines
5